Movement Disorders, Parkinson's Disease
Read Time: 7 mins

Imaging, Cognition, and Parkinson’s Disease—An Overview

Copy Link
Published Online: Jun 4th 2011 US Neurology, 2010;5(2):26-29 DOI:
Authors: Paul Mattis, David Eidelberg
Quick Links:
Article Information

Although the clinical diagnosis of Parkinson’s disease (PD) is defined by motor symptoms, cognitive dysfunction is a common manifestation of this disease and an important contributor to functional disability. Functional brain imaging tools have proved valuable in the study of cognitive impairment in PD. Recent advances in imaging methodology and analysis have provided novel insights into the pathophysiology of cognitive decline in these patients. This review summarizes how positron emission tomographic (PET) imaging of metabolic activity in the rest state has enhanced understanding of cognitive dysfunction in PD. This tool has also created the basis for an objective biomarker for use in clinical trials of new therapeutic agents for this disease manifestation. Moreover, insights gained from the use of specific radiotracers targeting the dopaminergic and cholinergic neurotransmitter systems will be discussed, as well as findings from in vivo detection of amyloid-beta.


Brain networks, positron emission tomography, Parkinson’s disease, metabolism, cognition, dopaminergic system, cholinergic system, protein aggregation


Parkinson’s disease (PD) is characterized by motor symptoms including resting tremor, rigidity, and bradykinesia. However, cognitive and behavioral problems in PD are common1 and can have a significant effect on quality of life.2,3 The prevalence of dementia in patients with PD has conservatively been estimated to range between 24 and 31%.4 The cognitive profile observed in PD patients with dementia (PDD) is substantially different from that of the primarily cortical dementia of Alzheimer’s disease (AD). Patients with PDD typically exhibit difficulties with executive functions, the retrieval aspects of memory, and visuospatial skills.4 They do not exhibit clear aphasia, apraxia, or agnosia, which are common features of AD. The onset of dementia in PD is insidious, typically occurring years after the onset of motor symptoms. However, cognitive difficulties have been observed even in early PD.5 Although debated, the pattern of early cognitive dysfunction in PD is believed to be generally similar to that of PDD.6,7

The pathophysiology of cognitive symptoms in PD is believed to be different from that of the motor symptoms.8–10 Several theories exist regarding the origins of this particular clinical manifestation. It is possible that cognitive dysfunction in PD is related to the depletion of striatal dopamine and its effect on non-motor cortico–striato–pallidal– thalamocortical (CSPTC) circuits.6 Nevertheless, other dopaminergic systems may mediate these cognitive changes, including mesocortical dopamine projections to the prefrontal cortex.11,12 Other pathological processes, such as regional cortical Lewy body formation, are also likely to contribute to PD cognitive decline,13 as well as abnormalities of other neurotransmitter systems.14 Metabolic Imaging
18F-fluorodeoxyglucose (FDG) PET imaging has revealed widespread cortical hypometabolism in advanced PD patients relative to healthy controls.15 Among patients with PD, those with dementia exhibit relatively greater metabolic reductions in both frontal and parietal regions.16 Although not widely investigated, several imaging studies support the idea that multiple cortical regions are associated with changes in cognition. For example, performance on a complex spatial conceptual task (Raven’s Colored Progressive Matrices) was found to be associated with reduced metabolic activity in the dorsolateral prefrontal cortex (DLPFC) and in the right retrosplenial region and posterior cingulate region.17 Furthermore, changes in mesial frontal activity observed in normal controls performing a gambling task was not present in non-demented PD patients.18

To identify metabolic brain networks associated with PD, we have applied a voxel-based spatial covariance approach to the analysis of PET data.19 This approach allows for the identification of abnormal diseaserelated metabolic patterns (i.e. brain networks) and the quantification of the expression of known patterns (i.e. network activity) in individual subjects. Specific metabolic networks have been found to mediate the motor and cognitive aspects of PD (see Figure 1).7,19 These networks have been demonstrated to be robust descriptors of disease processes.

The motor manifestations of PD are associated with a highly reproducible disease-related spatial covariance pattern (PDRP) characterized by relative metabolic increases in pallidal, ventral thalamic, and pontine areas, associated with reductions in premotor and posterior cortical association regions.20 PDRP has been shown to be consistently correlated with standardized ratings of motor disability, and has been extensively validated as a treatment biomarker.21–23 A separate cognition-related spatial covariance pattern (PDCP) has also been identified and validated in non-demented PD patients.10 This pattern is characterized by metabolic reductions in frontal and parietal association areas, associated with relative metabolic increases in the cerebellum. Both the PDRP and PDCP have excellent test–re-test reproducibility. The PDCP has been demonstrated to correlate with neuropsychological measures specifically associated with subcortical dementia syndrome.10 Network expression is most strongly associated with performance on tests of memory and executive functioning. A relationship with visuospatial and perceptual motor speed has also been found.10

The PDCP does have some regional overlap with the PDRP. However, these network biomarkers are dissociable in multiple ways.7,10,23,24 In a longitudinal study7 we documented that PDRP expression is elevated in early disease, whereas a significant degree of PDCP network expression cannot be discerned until approximately six years after symptom onset. In other words, network expression parallels symptom onset, with the motor manifestations preceding cognitive dysfunction. In addition, PDRP expression is sensitive to pharmacological and surgical therapies directed at the motor manifestations of the disease.22,25 On the other hand, PDCP expression remains stable with these interventions, consistent with the lack of a treatment effect on cognitive functioning based on repeated psychometric testing.10,23

Subsequent studies have suggested that the PDCP is sensitive to early cognitive decline, as characterized by mild cognitive impairment (MCI).26,27 PDCP activity was found to increase in a stepwise fashion, with worsening cognitive categorization (see Figure 2). Healthy controlsubjects had lower PDCP expression than PD patients without MCI, who in turn had lower values than those with cognitive impairment. Moreover, patients with single-domain MCI maintained an intermediate position between those with involvement of multiple cognitive domains and those without cognitive impairment. PDD patients exhibit further PDCP elevations than MCI subjects.

The anatomical regions that contribute most to the PDCP network are the medial aspects of the lateral frontal and parietal association areas, and are therefore somewhat reminiscent of the ‘default mode network.’28 Therefore, it is possible that abnormal elevations in PDCP activity denote reduced capacity to allocate neural resources, as well as a diminution in cognitive reserve. Given the lack of a significant effect of levodopa on PDCP expression,10 this network is unlikely to be a simple reflection of mesocortical dopaminergic dysfunction. Moreover, PDCP regions do not generally display α-synuclein aggregation until later in the clinical course of disease.29 It is therefore possible that in early stages of disease, this cognition-related pattern reflects functional changes in non-dopaminergic systems. Indeed, cholinergic deficits have been documented in multiple PDCP areas.10,14,30 To date, there has been no direct comparison of PDCP expression and cholinergic functioning. Dopaminergic Imaging
The development of several ligands for use with PET has helped elucidate the role of different mechanisms associated with cognitive decline in patients with PD. Indeed, this disease is well suited to PET imaging studies of neurotransmitter function because of the availability of specific radiotracers targeting the dopamine (DA) system.

The use of 6-[18F]fluoro-L-dopa (FDOPA) with PET permits the study of pre-synaptic dopaminergic terminal function in the striatum. This imaging technique has been used extensively to document disease severity in PD, but has more recently been applied to study dementia in PD patients. Indeed, compared with cognitively normal PD patients, those with PDD have exhibited reduced FDOPA uptake bilaterally in the region of the anterior cingulate and ventral striatum, and in the rightcaudate nucleus.31 However, reduced cortical uptake of this tracer has not been universally reported as a feature of PDD.14

Striatal FDOPA uptake values have also been found to correlate with the degree of cognitive impairment present in non-demented PD patients. For example, when comparing non-demented PD patients with and without executive deficits, Cheesman et al.32 observed a relationship between striatal dopamine and executive functioning, but not with cortical or limbic dopamine. Similarly, Cropley and colleagues33 found that in PD patients, putamen uptake predicted performance on the number of categories achieved on the Wisconsin Card Sorting Test. Interestingly, this relationship did not exist for the caudate. This suggests that striatal dopamine denervation may contribute to some degree to frontostriatal cognitive impairment in moderate-stage PD. Overall, based on FDODA uptake, caudate dopamine is believed to be more closely associated with cognition than dopamine in the putamen,31,34 although it has been suggested that both regions are linked to different aspects of cognition,35 hypothesizing that the putamen is related to the executive aspect of motor initiation. Others have found that cortical FDOPA uptake in DLPFC and medial PFC is associated with executive functioning34,36 and conceptualization abilities.17

Other radiotracers have been extensively utilized with PET and singlephoton- emission computed tomography (SPECT) to measure striatal dopamine transporter (DAT) binding in PD.37 At our Center, we haveutilized [18F]fluoropropyl-βCIT (FPCIT) and PET in early PD to assess rates of change in DAT binding with disease progression.7 This radiotracer was also used in conjunction with [15O]-labeled water (H215O) PET to assess the relationship of DAT binding and sequence learning-related activation responses.38,39 We found a significant correlation between dopamine input to the caudate and cognitive functioning in early PD. This study also revealed a relationship between caudate DAT binding and PFC activation during sequence learning.

In summary, imaging research targeting the dopaminegic system supports the existence of a substantial contribution from the mesocortical and nigrostriatal pathways to cognitive functioning in PD. Nonetheless, these changes do not fully explain the impairment in cognitive functioning seen in these patients. Indeed, the behavioralresponse to dopaminergic treatment is complex and may involve a variety of phenotypic and genotypic factors.12

Cholinergic Imaging
It is not surprising that other neurotransmitter systems have been found to play a role in PD cognitive impairment. N-[11C]-methyl-4-piperidyl acetate (MP4A) and N-[11C]-methyl-4-piperidin-4-yl-propionate (PMP) are PET radioligands that assess the activity of acetylcholinesterase (AChE), the major enzyme for acetylcholine metabolism. Using these tracers, patients with PD have been found to exhibit a global reduction (~10%) in cholinergic activity, with more substantial reductions (20–30%) in those patients with PDD.14,40 This is consistent with pathological studies in which similar reductions in acetylcholine have been documented.30 PDD patients are reported to exhibit bilateral widespread reductions in MP4A binding compared with normal control subjects, while those without cognitive dysfunction exhibit reduced binding only in the left cuneus.14 Compared with PD, PDD patients had lower uptake in multiple cortical regions (left inferior parietal lobule, left precentral gyrus and right posterior cingulate gyrus). Interestingly, cortical MP4A did not correlate with local FDOPA uptake values. By contrast, striatal FDOPA uptake correlated with loss ofcholinergic activity in the temporoparietal cortex, suggesting that in PD the dopaminergic and cholinergic systems degenerate in parallel.14 Imaging Protein Aggregation
The development of the tracer N-methyl-[11C]2-(4’-methylaminophenyl)- 6-hydroxybenzothiazole (Pittsburgh Compound-B or PIB) has allowed for the in vivo detection of amyloid-beta (Aβ) burden.41 This radioligand binds to fibrillar Aβ plaques, one of the two main pathological elements of Alzheimer’s disease (AD). Patients with AD have been shown to have marked retention of PIB in association cortices, regions in which amyloid deposits are evident on histopathological studies.42 Although less frequent than in diffuse Lewy body disease (DLB), cortical Aβ aggregates can be found in approximately one-fifth of PDD patients,43 and elevatedPIB binding on PET imaging has been noted in a similar proportion of these patients.44–46 Interestingly, PDD patients with and without PIB activity do not appear to differ behaviorally,44,46 suggesting that focally increased amyloid deposition is not the cause of impaired cognitive functioning in these patients. PIB has been shown to bind to α-synuclein fibrils, although with a much lower affinity than to Aβ.47 Nevertheless, PIB does not bind to DLB homogenates that are Aβ-plaque-free.47 Thus, the role of α-synuclein aggregation in PD-related cognitive impairment remains an open issue. Moreover, the relationship between PIB burden and cognitive functioning has not been studied with comprehensive neuropsychological testing, although a clear relationship has been found with brief screening instruments.44

Although the clinical diagnosis of PD is based on motor symptoms, cognitive dysfunction is a significant element of this disease and contributes substantially to patient disability. Functional imaging studies have demonstrated that the mechanism of cognitive dysfunction in PD is complex. This manifestation of PD is likely to stem from dopaminergic and/or cholinergic dysfunction, as well as pathological changes intrinsic to the cerebral cortex. Some aspects of these changes are captured by the PDCP network, which can be quantified to assess cognition-related metabolic changes over time and/or with treatment. A detailed understanding of the role of individual regions in this network can be obtained through activation studies with H2 15O PET or functional MRI, as well as with specific radioligands to assess the integrity of ascending neurotransmitter pathways or the accumulation of cortical protein aggregates. Thus, PET imaging provides a useful means of testing new therapies for cognitive dysfunction in PD.

Article Information:

The authors have no conflicts of interest to declare.


David Eidelberg, MD, Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, 350 Community Drive, Manhasset, NY 11030. E:




  1. Emre M, Aarsland D, Brown R, et al., Clinical diagnostic criteria for dementia associated with Parkinson’s disease, Mov Disord, 2007;22:1689–1707.
  2. Aarsland D, Larsen JP, Karlsen K, et al., Mental symptoms in Parkinson’s disease are important contributors to caregiver distress, Int J Geriatr Psychiatry, 1999;14:866–74.
  3. Martinez-Martin P, Rodriguez-Blazquez C, et al., The clinical impression of severity index for Parkinson’s disease: International validation study, Mov Disord, 2009;24:211–17.
  4. Aarsland D, Zaccai J, Brayne C, A systematic review of prevalence studies of dementia in Parkinson’s disease, Mov Disord, 2005;20:1255–63.
  5. Foltynie T, Brayne CE, Robbins TW, Barker RA, The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study, Brain, 2004;127:550–60.
  6. Green J, McDonald WM, Vitek JL, et al., Cognitive impairments in advanced PD without dementia, Neurology, 2002;59:1320–24.
  7. Huang C, Tang C, Feigin A, et al., Changes in network activity with the progression of Parkinson’s disease, Brain, 2007;130:1834–46.
  8. Mentis MJ, McIntosh AR, Perrine K, et al., Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson’s disease, Am J Psychiatry, 2002;159:746–54.
  9. Lozza C, Baron JC, Eidelberg D, et al., Executive processes in Parkinson’s disease: FDG-PET and network analysis, Hum Brain Mapp, 2004;22:236–45.
  10. Huang C, Mattis P, Tang C, et al., Metabolic brain networks associated with cognitive function in Parkinson’s disease, Neuroimage, 2007;34:714–23.
  11. Bosboom J L, Stoffers D, Wolters E, Cognitive dysfunction and dementia in Parkinson’s disease, J Neural Transm, 2004;111:1303–15.
  12. Argyelan M, Carbon M, Ghilardi MF, et al., Dopaminergic suppression of brain deactivation responses during sequence learning, J Neurosci, 2008;28:10687–95.
  13. Kovari E, Gold G, Herrmann FR, et al., Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease, Acta Neuropathol, 2003;106:83–8.
  14. Hilker R, Thomas AV, Klein JC, et al., Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways, Neurology, 2005;65:1716–22.
  15. Hilker R, Voges J, Weisenbach S, et al., Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson’s disease, J Cereb Blood Flow Metab, 2004;24:7–16.
  16. Yong SW, Yoon JK, An YS, Lee PH, A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies, Eur J Neurol, 2007;14:1357–62.
  17. Nagano-Saito A, Kato T, Arahata Y, et al., Cognitive- and motor-related regions in Parkinson’s disease: FDOPA and FDG PET studies, Neuroimage, 2004;22:553–61.
  18. Thiel A, Hilker R, Kessler J, et al., Activation of basal ganglia loops in idiopathic Parkinson’s disease: a PET study, J Neural Transm, 2003;110:1289–1301.
  19. Eckert T, Tang C, Eidelberg D, Assessment of the progression of Parkinson’s disease: a metabolic network approach, Lancet Neurol, 2007;6:926–32.
  20. Ma Y, Tang C, Spetsieris PG, et al., Abnormal metabolic network activity in Parkinson’s disease: test-retest reproducibility, J Cereb Blood Flow Metab, 2007;27:597–605.
  21. Eckert T, Eidelberg D, Neuroimaging and therapeutics in movement disorders, NeuroRx, 2005;2:361–71.
  22. . Asanuma K, Tang C, Ma Y, et al., Network modulation in the treatment of Parkinson’s disease, Brain, 2006;129:2667–78.
  23. Feigin A, Kaplitt MG, Tang C, et al., Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson’s disease, Proc Natl Acad Sci U S A, 2007;104: 19559–64.
  24. Lin TP, Carbon M, Tang C, et al., Metabolic correlates of subthalamic nucleus activity in Parkinson’s disease, Brain, 2008;131:1373–80.
  25. Trost M, Su S, Su P, et al., Network modulation by the subthalamic nucleus in the treatment of Parkinson’s disease, Neuroimage, 2006;31:301–7.
  26. Huang C, Mattis P, Perrine K, et al., Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease, Neurology, 2008;70:1470–77.
  27. Janvin CC, Larsen JP, Aarsland D, Hugdahl K, Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia, Mov Disord, 2006;21:1343–9.
  28. Gusnard DA, Raichle ME, Searching for a baseline: functional imaging and the resting human brain, Nat Rev Neurosci, 2001;2:685–94.
  29. Braak H, Del Tredici K, Rub U, et al., Staging of brain pathology related to sporadic Parkinson’s disease, Neurobiol Aging, 2003;24:197–211.
  30. Bohnen N I, Kaufer DI, Ivanco LS, et al., Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study, Arch Neurol, 2003;60:1745–8.
  31. Ito K, Nagano-Saito A, Kato T, et al., Striatal and extrastriatal dysfunction in Parkinson’s disease with dementia: a 6- [18F]fluoro-L-dopa PET study, Brain, 2002;125:1358–65.
  32. Cheesman AL, Barker RA, Lewis SJ, et al., Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson’s disease, J Neurol Neurosurg Psychiatry, 2005;76:1204–10.
  33. Cropley V L, Fujita M, Bara-Jimenez W, et al., Pre- and postsynaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA, Psychiatry Res, 2008;163:171–82.
  34. Rinne J O, Portin R, Ruottinen H, et al., Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study, Arch Neurol, 2000;57:470–75.
  35. van Beilen M, Portman AT, Kiers HA, et al., Striatal FDOPA uptake and cognition in advanced non-demented Parkinson’s disease: a clinical and FDOPA-PET study, Parkinsonism Relat Disord, 2008;14:224–8.
  36. Bruck A, Aalto S, Nurmi E, et al., Cortical 6-[18F]fluoro-Ldopa uptake and frontal cognitive functions in early Parkinson’s disease, Neurobiol Aging, 2005;26:891–8.
  37. Au WL, Adams JR, Troiano AR, Stoessl AJ, Parkinson’s disease: in vivo assessment of disease progression using positron emission tomography, Brain Res Mol Brain Res, 2005;134:24–33.
  38. Carbon M, Ma Y, Barnes A, et al., Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in Parkinsonism, Neuroimage, 2004;21: 1497–1507.
  39. Carbon M, Eidelberg D, Functional imaging of sequence learning in Parkinson’s disease, J Neurol Sci, 2006;248:72–7.
  40. Bohnen NI, Kaufer DI, Hendrickson R, et al., Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia, J Neurol, 2006;253: 242–7.
  41. Fripp J, Bourgeat P, Acosta O, et al., Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer’s disease, mild cognitive impairment and healthy aging, Neuroimage, 2008;43:430–39.
  42. Klunk WE, Engler H, Nordberg A, et al., Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound- B, Ann Neurol, 2004;55:306–19.
  43. Ballard C, Ziabreva I, Perry R, et al., Differences in neuropathologic characteristics across the Lewy body dementia spectrum, Neurology, 2006;67:1931–4.
  44. Edison P, Rowe CC, Rinne JO, et al., Amyloid load in Parkinson’s disease dementia and Lewy Body dementia measured with [11C]PIB-PET, J Neurol Neurosurg Psychiatry, 2008;79:1331–8.
  45. Maetzler W, Reimold M, Liepelt I, et al., [11C]PIB binding in Parkinson’s disease dementia, Neuroimage, 2008;39:1027–33.
  46. Gomperts SN, Rentz DM, Moran E, et al., Imaging amyloid deposition in Lewy body diseases, Neurology, 2008;71: 903–10.
  47. Fodero-Tavoletti MT, Smith DP, McLean CA, et al., In vitro characterization of Pittsburgh compound-B binding to Lewy bodies, J Neurosci, 2007;27:10365–71.

Further Resources

Share this Article
Related Content In Parkinson's Disease
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72